Overview

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
Phase:
PHASE1
Details
Lead Sponsor:
Kymera Therapeutics, Inc.